Clinical trials: Placebo Response
Perioperative Pain
Dose-Response of Adenosine for Perioperative Pain
Adenosine A1 and A2 receptors are widely distributed in the brain and spinal cord and represent a non-opiate target for pain management.
- Trial name
- NCT00298636
- Testing
- adenosine
- Where
- 8 sites in United States
- Volunteers
- 160 people
- Sponsor
- Xsira Pharmaceuticals
Rheumatoid Arthritis
Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)
The objective of this trial is to investigate the efficacy (American College of Rheumatology 20% : ACR20) superiority of two dose regiments of CDP870 versus placebo in combination with MTX in active RA patients who have an…
- Trial name
- NCT00791999
- Testing
- CDP870 400mg, CDP870 200mg, CDP870 100mg
- Where
- 8 sites in Japan
- Volunteers
- 316 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Healthy
Acute Effects of a Botanical Extract and Its Main Volatile Compound on Stress Response in Healthy Adults
The prevalence of stress in daily human life increase in the investigator's modern life style. Short stress, could be benefit for memory, but prolonged stress may conduct to disturbance in cardiovascular, neuroendocrine and…
- Trial name
- NCT04523870
- Testing
- Botanical extract, Main compound of the botanical extract
- Where
- France
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Activ'inside
Rheumatoid Arthritis
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
This study is intended to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in combination with Methotrexate (MTX) for inducing and sustaining clinical response in the treatment of Disease Modifying Antirheumatic Drug…
- Trial name
- C-early (NCT01519791)
- Testing
- Certolizumab Pegol, Methotrexate
- Where
- 178 sites in United States, Argentina and 20 more
- Volunteers
- 880 people
- Sponsor
- UCB Pharma SA
Coronavirus, COVID
A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19
This was a randomized, double-blind, placebo-controlled, 29-day study to assess the efficacy and safety of axatilimab plus standard of care (SOC), compared with placebo plus SOC, in participants with respiratory signs and…
- Conditions
- Coronavirus, COVID, ARDS, Cytokine Storm
- Trial name
- NCT04415073
- Testing
- SNDX-6352
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Syndax Pharmaceuticals
Rheumatoid Arthritis
Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis
The purpose of this study is to assess whether BMS-817399 in combination with Methotrexate is effective in treating moderate to severe rheumatoid arthritis.
- Trial name
- RA (NCT01404585)
- Testing
- BMS-817399
- Where
- 29 sites in United States, Argentina and 5 more
- Volunteers
- 123 people
- Sponsor
- Bristol-Myers Squibb
Type 2 Diabetes
Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes
This is a 6-month study to evaluate the effects of monotherapy with rivoglitazone, an insulin sensitizer, on glycemic control in newly identified type 2 diabetics or diabetics not adequately treated with other antidiabetic…
- Trial name
- NCT00143520
- Testing
- Rivoglitazone, Pioglitazone
- Where
- 74 sites in United States
- Volunteers
- 441 people
- Sponsor
- Daiichi Sankyo
Diabetes Mellitus, Type 2
A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of CNTO 3649 following a single dose in healthy adults and following multiple doses in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT00882726
- Testing
- CNTO 3649 IV (Healthy participants), CNTO 3649 SC (Healthy participants), CNTO 3649 SC (Diabetic patients)
- Where
- 3 sites in United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Centocor, Inc.
Fibromyalgia
Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With Fibromyalgia
A correlation between increased norepinephrine concentration in the central nervous system (CNS) and a decrease in fibromyalgia pain has been suggested in clinical studies.
- Trial name
- FMS201 (NCT01323374)
- Testing
- Droxidopa, Carbidopa, Droxidopa/carbidopa
- Where
- 7 sites in United Kingdom
- Volunteers
- 122 people
- Sponsor
- Chelsea Therapeutics
Psoriatic Arthritis
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).
- Trial name
- KEEPsAKE 1 (NCT03675308)
- Testing
- Risankizumab
- Where
- 256 sites in United States, Argentina and 37 more
- Volunteers
- 964 people
- Sponsor
- AbbVie
Healthy Volunteer, Immune Response
LC-Plasma on Immune Response and Reducing Symptoms of Upper Respiratory Infectious Diseases
The goal of this study is to evaluate the effects of LC-Plasma on the innate and acquired immune systems, including the activation of pDCs, which play a role in virus elimination, as well as to assess its efficacy in reducing…
- Trial name
- NCT06837961
- Testing
- LC-Plasma
- Where
- Australia
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- RDC Clinical Pty Ltd
Psoriatic Arthritis
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
To examine the safety and efficacy of tofacitinib in subjects with active psoriatic arthritis who have previously had an inadequate response to at least one TNF inhibitor either due to lack of efficacy or an adverse event.
- Trial name
- OPAL BEYOND (NCT01882439)
- Testing
- Tofacitinib
- Where
- 125 sites in United States, Australia and 12 more
- Volunteers
- 395 people
- Sponsor
- Pfizer
Hypertension
A Study to Evaluate the Efficacy and Safety of Eplerenone in the Treatment of Hypertension in Children.
To evaluate the efficacy, safety, and toleration of eplerenone in the treatment of children aged 6 to 16 years with high blood pressure. The study will last approximately 10 weeks and about 320 patients will participate.
- Trial name
- NCT00147589
- Testing
- Eplerenone
- Where
- 41 sites in United States, Dominican Republic and 3 more
- Volunteers
- 320 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Psoriasis
A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Participants With Mild to Moderate Psoriasis
This is a parallel, Phase 1, single center, 2-arm, double-blind, randomized, placebo-controlled with a ratio 2 active: 1 placebo study for treatment of mild to moderate psoriasis participants.
- Trial name
- NCT05453942
- Testing
- SAR441566
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Sanofi
West Nile Fever
Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults
The purpose of this study is to determine whether a single subcutaneous injection of ChimeriVax-WN02 vaccine is well tolerated, safe and induces protective antibodies against West Nile Disease.
- Trial name
- NCT00442169
- Testing
- ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose
- Where
- 5 sites in United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Essential Tremor
Study to Evaluate SAGE-324 in Participants With Essential Tremor
The primary purpose of this study is to evaluate the dose-response relationship of different doses of SAGE-324 on upper extremity tremor in participants with essential tremor (ET) in the monotherapy cohort.
- Trial name
- NCT05173012
- Testing
- SAGE-324
- Where
- 51 sites in United States
- Volunteers
- 146 people
- Sponsor
- Sage Therapeutics
Crohn's Disease
A Study of Abatacept in Patients With Active Crohn's Disease
The purpose of this clinical research study is to learn if abatacept can improve signs and symptoms of active Crohn's Disease in patients who have not had an adequate response to other therapies.
- Trial name
- NCT00406653
- Testing
- abatacept
- Where
- 101 sites in United States, Australia and 15 more
- Volunteers
- 451 people
- Sponsor
- Bristol-Myers Squibb
Ulcerative Colitis
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis
The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission at 52 weeks.
- Trial name
- GEMINI I (NCT00783718)
- Testing
- vedolizumab
- Where
- 105 sites in United States, Canada and 1 more
- Volunteers
- 895 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Hepatitis C, Chronic
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
This phase 2b study will evaluate the efficacy and safety of 16 and 24 weeks of a 4-drug regimen with GS-9451 and Tegobuvir and 24 weeks of a 3-drug regimen of GS-9451 without Tegobuvir, all with Peginterferon Alfa-2a (Pegasys®)…
- Trial name
- NCT01271790
- Testing
- Tegobuvir (GS-9190), GS-9451, Pegasys®
- Where
- 144 sites in United States, Austria and 6 more
- Volunteers
- 245 people
- Sponsor
- Gilead Sciences
Smallpox, Mpox
A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age
The goal of this study is to assess the safety, tolerability and immunogenicity of mRNA-1769 in healthy adult participants.
- Trial name
- NCT05995275
- Testing
- mRNA-1769
- Where
- 12 sites in United Kingdom
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.